Dental Safety Profile of High-Dose Radioiodine Therapy

The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00439478

Enrollment

202

Registered

2007-02-23

Start date

2004-09-30

Completion date

2006-09-30

Last updated

2007-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Keywords

Radioiodine, Thyroid Cancer, Sialadenitis, Xerostomia

Brief summary

We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.

Detailed description

Sialadenitis and xerostomia are the most frequent adverse events of high-dose radioiodine therapy. Saliva has vital functions in maintaining periodontal and oral health. Therefore, xerostomia not only impairs quality of life permanently, but may also increase the risk of caries and tooth extractions. Nevertheless, despite more than 6 decades of radioiodine therapy for thyroid cancer, large studies on long-term oral adverse events are still lacking. In the present study, we investigate the influence of high-dose radioiodine therapy on the long-term oral health.

Interventions

DRUGRadioiodine

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* histologically confirmed differentiated thyroid cancer * status after total thyroidectomy * status after subsequent high-dose radioiodine treatment * regular follow-up by a board-certified dentist * a minimum follow-up of 1 year after radioiodine therapy.

Exclusion criteria

* anaplastic thyroid cancer

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026